"Results of RELATIVITY-047 will be made available for...

"Results of RELATIVITY-047 will be made available for presentation at an upcoming medical meeting and will be discussed with regulatory authorities." (BMS)
Data supporting the efficacy of the combination in patients with melanoma were previously presented at the European Society for Clinical Oncology 2017 Congress, which were taken from a phase 1/2 trial (NCT01968109) of relatlimab plus nivolumab in patients with disease progressing on prior anti–PD-1/L1 therapy.
Seven of 61 evaluable patients (11.5%) had an objective response to therapy; alternatively, patients with LAG-3—positive tumors demonstrated a response rate of 18%.
Stable disease was noted in 23 patients, resulting in a disease control rate (DCR) of 49%.
In patients whose tumors expressed 1% or more LAG-3, the disease control rate was 64%, comprised of 1 complete response, 5 partial responses, and stable disease in 15.
Notably, patients whose tumors did not harbor a BRAF mutation had higher responses compared with those who did; the presence of LAG-3 expression (≥1%) in conjunction with a BRAF mutation made those patients more likely to respond.